For a long time, AbbVie’s Humira was the world’s top-selling drug. But the bestseller will finally face biosimilar competition. Plus, this year is also chock-full of other big-name, blockbuster drugs headed for the patent cliff. In this episode, we discuss 2023's patent story. 

Plus, we cover how Johnson & Johnson is looking to end its talc litigation with a sweeping settlement and more of this week's top headlines. 

To learn more about the topics in this episode: 

• The top 10 drugs losing US exclusivity in 2023
• J&J proposes $8.9B talc settlement deal but some plaintiffs decry 'woefully inadequate' offer
• FTC reverses course, orders Illumina to unravel Grail deal
• Cytokinetics' pipeline tumble continues after ALS med flops in phase 3 interim look
• Ahead of Pfizer buyout, Seagen's Padcev gains Keytruda combo nod in first-line bladder cancer
• Butterfly nets AI ultrasound clearance for spotting signs of lung disease
• Intra-Cellular crowned your winner of the Fierce Madness Drug Ad Tournament 2023

"The Top Line" is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.